By virtue of its higher accuracy for the diagnosis of symptomatic AD compared to amyloid-PET [11, 16, 27, 28, 31], we expect that the impact of tau-PET in clinical practice will be similar or even higher than that of amyloid-PET. Here, MAPT is linked to Alzheimer disease.